2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Jason Niu, MD, PhD, discusses treatment updates in RET fusion–positive and KRAS-mutant non–small cell lung cancer.
Jason Niu, MD, PhD, director of the Lung Cancer Program, Banner MD Anderson Cancer Center, discusses treatment updates in RET fusion–positive and KRAS-mutant non–small cell lung cancer (NSCLC).
For patients with RET fusion–positive NSCLC, 2 promising options exist in the space, including pralsetinib (Gavreto) and selpercatinib (Retevmo), according to Niu. It is important that experts within the field familiarize themselves with at least 1 of these agents and feel comfortable with its use, as they are both great first-line options, Niu explains. The earlier these agents are used, the more patients will experience benefit, he continues.
Secondly, the field should be on the lookout for the FDA approvals of sotorasib (Lumakras) and adagrasib (MRTX 849). For those who are not enrolling their patients on clinical trials, within the near future, new agents should be approved for this challenging to treat patient population, Niu concludes.